MBX Biosciences, Inc.
About MBX Biosciences, Inc.
MBX Biosciences Inc is a clinical stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. The company designed its proprietary Precision Endocrine Peptide, or PEP, platform to overcome the key limitations of unmodified and modified peptide therapies to improve clinical outcomes and simplify disease management for patients. Its PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. Its product candidates include canvuparatide (MBX 2109), imapextide (MBX 1416), and MBX 4291.
This profile is unclaimed. An authorized representative can claim it to add details and earn the Verified badge.
Financial summary
- Net income
- -$87.0M
- Total assets
- $385.1M
- Market cap
- $1.4B
Source: SEC EDGAR · updated Jun 7, 2026
Revenue & profit trend
Financial statements
Income statement
- Revenue
- $0
- Operating expenses
- $98.1M
- Operating income
- -$98.1M
- Income tax
- $0
- Net income
- -$87.0M
- EPS (basic)
- $-2.38
- EPS (diluted)
- $-2.38
Balance sheet
- Total assets
- $385.1M
- Current assets
- $381.5M
- Total liabilities
- $15.9M
- Current liabilities
- $15.5M
- Shareholders’ equity
- $369.2M
Cash flow
- Operating cash flow
- -$79.9M
- Investing cash flow
- -$83.7M
- Financing cash flow
- $189.6M
- Net cash flow
- $25.9M
Statements via Polygon.io (SEC filings)
15-minute delayed · data by Polygon.io
Past year
52-week range
- Market cap
- $1.4B
- EPS (diluted)
- $-2.38
- Shares outstanding
- 49.7M
- Open
- —
- Day range
- –
- Prev close
- —
- Volume
- —
- IPO date
- Sep 13, 2024
Market data by Polygon.io · prices are 15-minute delayed
At a glance
- Reported a net loss of $87.0M.
- Trading 33% below its 52-week high.
Automatically generated from public filings and market data. Informational only — not investment advice or a recommendation to buy or sell any security.
No reviews yet. Be the first to review MBX Biosciences, Inc..
Write a review
News about MBX Biosciences, Inc.
News & sentiment via Polygon.io
